Abstract: Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulatory proteins in the cell division and proliferative cycle in humans. They are overactive in many malignant tumors, particularly in triple-negative breast cancer (TNBC). Inhibition of CDK4/6 targets can have anti-tumor effects. Here, we designed and synthesized a novel derivative of Ribociclib that could affect CDK4/6, named WXJ-202. This study aimed to investigate the effects of compound WXJ-202 on proliferation, apoptosis, and cell cycle arrest in human breast cancer cell lines and their molecular mechanisms. WXJ-202 was shown to inhibit cell proliferation, colony formation, migration, and invasion, as well as induce apoptosis and cycle arrest in breast cancer cells. The levels of proteins related to the CDK4/6-Rb-E2F pathway, such as CDK4, CDK6, and p-Rb, were decreased. Finally, studies had shown that compound WXJ-202 exhibited significant anti-tumor activity in transplantation tumor models. In this research, the compound WXJ-202 was shown to have better anti-tumor cell proliferative effects and could be used as a potential candidate against TNBC tumors.
Introduction
Breast cancer remains a leading cause of mortality among women globally. A particularly challenging subtype is Triple-Negative Breast Cancer (TNBC), which lacks the three most common therapeutic receptors (estrogen, progesterone, and HER2). This makes TNBC highly invasive and difficult to treat with standard targeted therapies. While CDK4/6 inhibitors like Ribociclib have revolutionized treatment for other breast cancer types, TNBC often shows limited response or develops drug resistance. This research presents WXJ-202, a "next-generation" molecule designed to bind more effectively to CDK4/6 kinases to provide a more potent option for TNBC patients.
Methods and Chemical Synthesis
The development of WXJ-202 involved a combination of computational design and traditional chemical synthesis. Researchers utilized molecular docking (AutoDockTools) to simulate interactions with CDK4 and CDK6 binding pockets. The compound, a 7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide derivative, was synthesized with a 56.6% yield.
Biological validation included MTT assays for cell viability, wound healing and transwell assays for migration and invasion, and flow cytometry for cell cycle and apoptosis analysis. Protein expression was tracked via Western blotting. In vivo efficacy was evaluated using a Chicken Embryo Chorioallantoic Membrane (CAM) model, providing a cost-effective alternative for early-stage drug testing.
Molecular Mechanism and Binding Affinity
Molecular docking revealed that WXJ-202 forms a more stable complex with CDK4/6 compared to its parent drug, Ribociclib. Specifically, WXJ-202 forms three distinct hydrogen bonds with CDK4 at residues LYS 35, ILE 12, and ARG 101. This enhanced structural "tightness" is a key factor in its superior inhibitory performance.
By effectively targeting the CDK4/6-Rb-E2F pathway, WXJ-202 prevents the phosphorylation of the Retinoblastoma (Rb) protein. This keeps the E2F transcription factor inactive, halting the cell cycle at the G0/G1 phase and preventing entry into the S-phase (DNA synthesis).
Key Results
- Enhanced Potency: In MDA-MB-231 TNBC cells, WXJ-202 achieved an IC50 of 9.31 μM, nearly four times more potent than Ribociclib (34.96 μM).
- Cell Cycle Arrest and Apoptosis: Treatment with 40 μM of WXJ-202 increased the G0/G1 phase population to 75.8% (vs. 42.9% in control) and induced apoptosis in approximately 46% of cells.
- In Vivo Efficacy: In the CAM model, high-dose WXJ-202 reduced tumor weight by approximately 67% and significantly inhibited tumor-related angiogenesis.
- Anti-Metastatic Potential: The compound significantly inhibited the migration and invasion of aggressive TNBC cells, suggesting potential in preventing tumor spread.
Conclusion and Future Directions
WXJ-202 represents a promising advancement in the development of CDK4/6 inhibitors for aggressive breast cancers. While the CAM model results are encouraging, future work must transition to mammalian xenograft models to confirm systemic safety and efficacy. Additionally, further research is needed to determine if WXJ-202 can overcome the resistance mechanisms that often limit the clinical utility of first-generation CDK4/6 inhibitors.
Summary updated